Small-molecule ghrelin mimetic · Fact sheet
Ibutamoren
Also known as MK-677 · MK-0677 · Ibutamoren mesylate
Ibutamoren, often called MK-677, is a small molecule rather than a peptide or SARM. It increased growth hormone and lean mass in older adults, but did not improve strength or function in that trial and remains unapproved.
What is Ibutamoren?
Ibutamoren acts through the ghrelin receptor and stimulates the growth-hormone/IGF-1 pathway. A change in lean mass includes more than new functional muscle.
Benefits & claims
People look for greater appetite, muscle growth, recovery, sleep, and anti-aging effects. The human findings are more limited than this collection of claims.
What the evidence supports
- The older-adult trial found increases in growth hormone, IGF-1, and fat-free mass.
- It did not demonstrate better strength or physical function; hip-fracture findings were also unfavorable overall.
Research areas
- Age-related body composition
- Growth hormone and IGF-1
- Recovery after hip fracture
Dosage & frequency
Human study contextA human trial tested oral ibutamoren in older adults. Increased GH, IGF-1 or lean mass does not establish improved strength, function, or safe anti-aging use.
Randomized older-adult trial
65 healthy adults age 60–81
- Amount
- 25 mg
- Frequency
- Once daily in a two-year study
- Route studied or labeled
- Oral
Lean-mass and hormone findings did not establish improved strength or function.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Ibutamoren/MK-677 is a small-molecule ghrelin-receptor agonist, not a peptide.
Interactions & precautions
- The older-adult trial does not establish safety with other GH-directed treatments or diabetes medicines; changes in glucose handling matter to this evidence gap.
What is still unresolved
- A favorable long-term benefit–risk balance and clinically useful treatment population remain unestablished.
Side effects & risks
- Increased appetite, edema, muscle discomfort, higher fasting glucose, and reduced insulin sensitivity were reported in the older-adult trial.
- A hip-fracture trial was stopped for a congestive-heart-failure signal; risk may depend on the population.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceA randomized study in 65 older adults found more fat-free mass without corresponding strength or function gains. A separate hip-fracture study was stopped early after a heart-failure safety signal.
Studies
Randomized study in 65 adults; lean-mass increase without strength or functional improvement.
123-participant Phase IIb study terminated early after a heart-failure signal.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 4 sourced accounts by reported effect.
Appetite: reported experiences
Better sleep alongside strong hunger
An author described better sleep and unusually strong hunger during their first three days with MK-677 while also using tirzepatide. Later hunger became easier to manage after tirzepatide changed.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Three days at the initial report
Other exposures described: Tirzepatide; its schedule changed during the discussion
Concurrent tirzepatide prevents isolating the effects. The author explicitly said it was too early to assess muscle-related claims.
Read the original accountNo added hunger, with possible better sleep
The original poster described no added hunger and little change apart from possible better sleep during MK-677 use.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- 10 mg
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Earlier RAD140 exposure, not described as concurrent
Despite the forum name, ibutamoren is not a SARM. Previous other-drug exposure, unverified products and subjective outcomes limit interpretation; this account does not establish muscle gain.
Read the original MK-677 accountPerceived recovery with intolerable hunger and fatigue
A different commenter described easier recovery between workouts, but hunger cramps, lethargy and fluid retention that they found intolerable during solo MK-677 use.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- 10 mg
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Not specified clearly
This is a separate person's experience from the original post. Frequency, product identity and measured outcomes are unverified; subjective recovery does not establish muscle gain.
Read the separate commenter's accountEnergy: reported experiences
Perceived injury recovery with unwanted fatigue and swelling
A commenter described improvement in an injury during months of MK-677 use, but also lethargy, fluid retention, poorer training and elevated blood sugar. In a reply, they disclosed diabetes susceptibility and substantial dietary changes.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- A little less than one year
Blood results and the injury were not independently verified. The follow-up’s dietary and health context prevents assigning the glucose change solely to MK-677.
Read the original accountPerceived recovery with intolerable hunger and fatigue
A different commenter described easier recovery between workouts, but hunger cramps, lethargy and fluid retention that they found intolerable during solo MK-677 use.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- 10 mg
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Not specified clearly
This is a separate person's experience from the original post. Frequency, product identity and measured outcomes are unverified; subjective recovery does not establish muscle gain.
Read the separate commenter's accountSleep: reported experiences
Better sleep alongside strong hunger
An author described better sleep and unusually strong hunger during their first three days with MK-677 while also using tirzepatide. Later hunger became easier to manage after tirzepatide changed.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Three days at the initial report
Other exposures described: Tirzepatide; its schedule changed during the discussion
Concurrent tirzepatide prevents isolating the effects. The author explicitly said it was too early to assess muscle-related claims.
Read the original accountNo added hunger, with possible better sleep
The original poster described no added hunger and little change apart from possible better sleep during MK-677 use.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- 10 mg
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Earlier RAD140 exposure, not described as concurrent
Despite the forum name, ibutamoren is not a SARM. Previous other-drug exposure, unverified products and subjective outcomes limit interpretation; this account does not establish muscle gain.
Read the original MK-677 accountStrength: reported experiences
Perceived recovery with intolerable hunger and fatigue
A different commenter described easier recovery between workouts, but hunger cramps, lethargy and fluid retention that they found intolerable during solo MK-677 use.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- 10 mg
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Not specified clearly
This is a separate person's experience from the original post. Frequency, product identity and measured outcomes are unverified; subjective recovery does not establish muscle gain.
Read the separate commenter's accountPain: reported experiences
Perceived injury recovery with unwanted fatigue and swelling
A commenter described improvement in an injury during months of MK-677 use, but also lethargy, fluid retention, poorer training and elevated blood sugar. In a reply, they disclosed diabetes susceptibility and substantial dietary changes.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- A little less than one year
Blood results and the injury were not independently verified. The follow-up’s dietary and health context prevents assigning the glucose change solely to MK-677.
Read the original accountGlucose: reported experiences
Perceived injury recovery with unwanted fatigue and swelling
A commenter described improvement in an injury during months of MK-677 use, but also lethargy, fluid retention, poorer training and elevated blood sugar. In a reply, they disclosed diabetes susceptibility and substantial dietary changes.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- A little less than one year
Blood results and the injury were not independently verified. The follow-up’s dietary and health context prevents assigning the glucose change solely to MK-677.
Read the original accountFluid retention: reported experiences
Perceived injury recovery with unwanted fatigue and swelling
A commenter described improvement in an injury during months of MK-677 use, but also lethargy, fluid retention, poorer training and elevated blood sugar. In a reply, they disclosed diabetes susceptibility and substantial dietary changes.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- A little less than one year
Blood results and the injury were not independently verified. The follow-up’s dietary and health context prevents assigning the glucose change solely to MK-677.
Read the original accountPerceived recovery with intolerable hunger and fatigue
A different commenter described easier recovery between workouts, but hunger cramps, lethargy and fluid retention that they found intolerable during solo MK-677 use.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- 10 mg
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Not specified clearly
This is a separate person's experience from the original post. Frequency, product identity and measured outcomes are unverified; subjective recovery does not establish muscle gain.
Read the separate commenter's accountNo clear change: reported experiences
No added hunger, with possible better sleep
The original poster described no added hunger and little change apart from possible better sleep during MK-677 use.
Reported use in this account
- Product
- Product described as MK-677
- Amount
- 10 mg
- Frequency
- Daily
- Route
- Not specified clearly
- Duration
- Not specified clearly
Other exposures described: Earlier RAD140 exposure, not described as concurrent
Despite the forum name, ibutamoren is not a SARM. Previous other-drug exposure, unverified products and subjective outcomes limit interpretation; this account does not establish muscle gain.
Read the original MK-677 accountApproval status
Ibutamoren has no FDA-approved product. Historical trials in older adults do not establish approval for bodybuilding, recovery, or anti-aging.
No FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether body-composition changes improve long-term function
- Long-term cardiovascular and glucose effects
- Benefits and harms in younger performance-oriented users
Summary
MK-677 can change hormones and body composition, but the trials do not support equating those changes with better performance or healthy aging.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- pubmedIbutamoren in healthy older adults
Randomized study in 65 adults; lean-mass increase without strength or functional improvement.
- pubmedIbutamoren after hip fracture
123-participant Phase IIb study terminated early after a heart-failure signal.